 | | Vol. 2.29 – 16 August, 2021 |
| |
|
|
| In mice with subcutaneous tumors, locally injected T cells with the inducible CAR and activated via focused ultrasound guided by magnetic resonance imaging mitigated on-target off-tumor activity and enhanced the suppression of tumor growth, compared with the performance of non-inducible CAR-T cells.
[Nature Biomedical Engineering] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors used the model to track the infiltration of a number of candidate stem cells and to characterize the expression levels of genes associated with post-stroke pathologies.
[Nature Biomedical Engineering] |
|
|
|
| Researchers sorted 12 murine adult hematopoietic cell populations at different stages and identified 30,796 editing sites through RNA sequencing. While the dynamic landscape of the RNA editome comprised of stage/group-specific and stable editing patterns, but it also underwent significant changes during lineage commitment.
[Blood] |
|
|
|
| Scientists showed that human T cells engineered to express an methyl-lysophosphatidic acid (mLPA)-specific TCR, targeted diverse CD1c-expressing leukemia blasts in vitro and significantly delayed the progression of three models of leukemia xenograft in NSG mice, an effect that was boosted by mLPA-cellular immunization.
[Nature Communications] |
|
|
|
| Investigators tested the participation of calcium-activated potassium-channels in human heart explant-derived cell physiology and therapeutic potential.
[Nature Communications] |
|
|
|
| The authors generated programmed cell death protein-1 (PD-1) and T cell receptor deficient mesothelin-specific CAR-T cells using CRISPR-Cas9 technology and evaluated them in a dose-escalation study.
[Cellular & Molecular Immunology] |
|
|
|
| Researchers found that interleukin-10 receptor (IL-10R) was overexpressed in most acute myeloid leukemia cells, and played an important role in promoting the stemness of leukemia cells.
[Blood Cancer Journal] |
|
|
|
| Coinjections of endothelial progenitor cells + mesenchymal stem cells significantly enhanced the survival rate of lipopolysaccharide-induced mice, decreased concentrations of pro-inflammatory cytokines, and increased the level of anti-inflammatory cytokine.
[Journal of Cellular Biochemistry] |
|
|
|
| CAR T cells were designed using a ligand binding domain instead of a single chain variable fragments to target stem-like leukemia cells. Thrombopoietin, the natural ligand to the myeloproliferative leukemia protein (MPL) receptor, was used as the antigen binding domain to engage MPL expressed on hematopoietic stem cells and erythropoietic and megakaryocytic acute myeloid leukemias.
[Gene Therapy] |
|  |
|
|
|
| The authors review current approaches to sample processing and computational analysis regarding their application to translational cancer immunotherapy research.
[Cancer Cell] |
|
|
|
| Investigators outline how epigenetic modifications in CAR T cells can overcome barriers limiting CAR T cell effectiveness, particularly in immunosuppressive tumor microenvironments.
[Molecular Therapy] |
|
|
|
| In this review, advances in vascular tissue engineering are described and discussed with a particular focus on the construction approaches of cellularized small-caliber tissue-engineered vascular grafts, the cell types used, as well as their preclinical and clinical applications.
[NPJ Regenerative Medicine] |
|
|
|
|
| A clinical trial of a gene therapy for a rare neurological disease is on hold after a participant in the study developed a bone marrow disorder that can lead to leukemia, the trial’s sponsor, bluebird bio, announced.
[ScienceInsider] |
|
|
|
| NexImmune, Inc. announced a collaboration with Yale University’s Department of Immunobiology. The collaboration will focus on the use of NexImmune’s direct injection, artificial antigen presenting cells with regards to the regulation of autoimmune diabetes, Type 1 diabetes.
[NexImmune, Inc.] |
|
|
|
| IN8bio, Inc. announced completion of dosing of the first patient cohort in a Phase I clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant.
[IN8bio, Inc.] |
|
|
|
| Athersys, Inc. announced that its partner, HEALIOS K.K., has completed enrollment in its TREASURE study in Japan, evaluating MultiStem® cell therapy treatment in patients who have suffered an ischemic stroke.
[Athersys, Inc.] |
|
|
|
|
| January 12 – 14, 2022
Shanghai, China |
|
|
|
|
|
| | University Of Wisconsin–Madison – Madison, Wisconsin, United States |
|
|
|
| | University Medical Center Utrecht – Utrecht, Netherlands |
|
|
|
| | The Geneva Foundation – Tacoma, Washington, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Incyte – Wilmington, Delaware, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
